We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Codiak Biosciences Inc (CDAK) USD0.0001

Sell:$11.50 Buy:$13.97 Change: $0.22 (1.76%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Change: $0.22 (1.76%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Change: $0.22 (1.76%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The Company's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The Company's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).

Contact details

35 CambridgePark Drive, Suite 500
United States
+1 (617) 9494100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$297.24 million
Shares in issue:
22.37 million
United States
US dollar

Key personnel

  • Douglas Williams
    President, Chief Executive Officer, Director
  • Linda Bain
    Chief Financial Officer, Treasurer
  • Yalonda Howze
    Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
  • Nicole Barna
    Senior Vice President - Human Resources
  • Konstantin Konstantinov
    Chief Technology Officer
  • Sriram Sathyanarayanan
    Chief Scientific Officer
  • Richard Brudnick
    Chief Business Officer, Head of Corporate Strategy
  • Jennifer Wheler
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.